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The World Health Organization estimates that global vaccina-
tion programs save 2 to 3 million lives per year by priming the
immune system to protect against pathogenic threats that pose
significant global health and economic burdens (Fig 1, A).1 In
addition to individual protection, vaccination programs also
rely on population or ‘‘herd’’ immunity: immunization of large
portions of the population to protect the unvaccinated, immuno-
compromised, and immunologically naive by reducing the num-
ber of susceptible hosts to a level less than the threshold needed
for transmission. For example, immunization of greater than
80% of the global population against smallpox virus reduced
transmission rates to uninfected subjects to a point low enough
to achieve eradication of the virus.1 Similarly, although the extent
of coverage needed is pathogen specific, poliovirus is now tar-
geted for eradication, with only Pakistan, Afghanistan, and
Nigeria documenting endemic viral infections.1
Despite the success of select vaccination programs (Fig 1, B),2
societal and biological factors, including the inability of popula-
tion groups to generate protective immunity in response to vacci-
nation, are a challenge for achieving herd immunity. The
unvaccinated, including the very young and aged and those who
are immunocompromised because of infection, congenital condi-
tions, or medical history, must be protected by passive immunity.
For example, unvaccinated female subjects benefit from human
papillomavirus (HPV) vaccination of their male partners because
HPV strains 16 and 18 are linked to 70% to 80% of cases of cer-
vical cancer.3 Although both male and female subjects can be in-
fected with HPV, female subjects are more likely to experience
detrimental oncogenic effects, including loss of reproductive ca-
pabilities. The vaccination of female and male subjects in young
populations with attenuated vaccines of the circulating HPV
strains has decreased transmission of these specific HPV viruses
to young unvaccinated female subjects in Scotland andAustralia.3
Thus vaccination of the potential carriers within the population
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vaccine responses. These issues pose challenging obstacles to the
development of vaccine-induced, broadly protective long-lasting
immunity. Immunosenescence refers to the progressive loss of
responsiveness to a pathogen, resulting in decreased antibody
titers or cellular responses and requiring booster vaccinations to
restore immunity. In the late 20th century, measles was nearly
eradicated in China, Korea, and the United States as a result of
early-age vaccination and boosters with attenuated virus.4,5 How-
ever, reintroduction of the wild-type virus into these localities has
caused spikes of infection in immunized middle-aged adults and
has been linked to the wild-type measles virus’ capacity to over-
come reduced antibody titers in these more aged populations,4,5
indicating a prospective need for a tertiary booster in adults to
bolster neutralization titers.
The breadth and length of duration of herd immunity are also
dependent on characteristics of the pathogen and its interactions
with the immune system. Antigenic drift, antigenic shift, and
recombination result in antigenic diversity within a pathogen
pool, and a viral species can consist of multiple variants that are
antigenically distinct from each other. The lack of a proofreading
function associated with most RNA polymerases makes RNA
viruses particularly adept at generating strain diversity. For
example, norovirus, the leading cause of acute gastroenteritis,
has more than 30 genotypes. The GII.4 genotype evolves rapidly
at surface epitopes that are key targets of protective immunity/
neutralizing antibodies.6 Despite maintaining 93.9% amino acid
sequence homology between the earliest and most recent known
pandemic strains, evolution at hypervariable epitopes correlates
with pandemic bursts of disease approximately every 2 to 5 years.
The immunocompromised, immunosenescent, and young chil-
dren have been postulated to be norovirus reservoirs. In these pop-
ulations a suppressed or naive immune system might not fully
neutralize every viral variant. Lower immune pressure on the vi-
rus, along with an error-prone RNA polymerase, allows for
mutated variants to emerge and escape neutralization.
Pathogen–immune response interactions also shape dengue
and influenza virus immunity and subsequent vaccine design.
Dengue virus circulates as 4 serotypes (DENV1-4), which have
roughly 70% sequence homology. Infection with one serotype
induces production of both cross-reactive and serotype-specific
neutralizing antibodies during initial infection.7,8 On infection
with a second serotype, the original memory immune response
is stimulated preferentially. Because of antigenic differences be-
tween the primary and secondary viruses, pre-existing antibody is
unable to effectively neutralize the second virus, allowing im-
mune evasion through immune imprinting (original antigenic
sin/antigenic seniority).7,8 Importantly, depending on the level
and neutralization capacity of the cross-reactive pre-existing an-
tibodies, a secondary infection can cause severe disease.8 Simi-
larly, the immune system preferentially recalls memory
antibody responses to the earliest infecting strains of influenza
FIG 1. Biological and societal factors affecting vaccine-induced population immunity (A) and the effect of
vaccination on prevalence of annual cases of Haemophilus influenzae b (Hib; 1986-1990), measles (1950-
1954), pertussis (1938-1942), and poliomyelitis (1950-1954) in Canada before and after the vaccine era
(B).2 Solid bars represent annual cases before the vaccine era (dates listed above), whereas hatched bars
represent annual cases after the vaccine era (2007-2011). Fig 1, B, is a reproduction of the data made publicly
available at the Chief Public Health Officer’s Report on the State of Public Health in Canada 2013-
Immunization and Vaccine-Preventable Diseases-Staying Protected (https://www.canada.ca/content/dam/
phac-aspc/migration/phac-aspc/cphorsphc-respcacsp/2013/assets/pdf/2013-eng.pdf).Avirus and norovirus and shows weaker consecutive responses to
infection with subsequent serotypes, respectively.6,8,9 Because
the herd is composed of subjects from many different age groups
and pandemic influenza and norovirus strains change over time,
effective vaccine development that induces broad protection is
highly complicated by age and pre-exposure history. Conserved
epitopes are potential vaccine targets for these and other patho-
gens that are susceptible to antigenic drift/shift and recombina-
tion. Although progress toward a universal influenza vaccine is
being made, protection currently relies on regular vaccination
withmultiple attenuated circulating strains to reduce transmission
and mitigate disease severity.9,10 Despite a global surveillance
network, predicting future flu epidemic strains for vaccine
production is high risk because of evidence of influenza
vaccine–contemporary strain mismatches in both 2014-2015
and 2017-2018.10Norovirus, dengue virus, and influenza virus illustrate chal-
lenges in eliciting broad immunity through vaccination with a
single serotype of attenuated virus. Although vaccination would
protect against the vaccinated serotype, it has the potential to
increase the severity of a secondary infection by inducing a
dampened response to later variants based on antigenic variation,
imprinting, and timing between inoculation and secondary
infection and/or immune enhancement.7-9 Research focusing on
protective immunity correlates, particularly cross-reactive
neutralizing antibody titers, and chimeric serotype–attenuated vi-
ruses to elicit broad immunity is underway. Understanding and
optimizing these factors can induce broad immunity across
populations.
As vaccines that can overcome the challenges of poor immune
responsiveness in hosts and antigenic diversity in pathogens are
developed, public policy plays a critical role in achieving the high
1. World Health Organization Media Center. Immunization Coverage. Available at:
http://www.who.int/mediacentre/factsheets/fs378/en/. Accessed December 20,
2017.
population vaccination rate needed to achieve herd immunity and 
freedom from disease. Universal access to affordable health care 
is of the highest priority because subjects of lower socioeconomic 
status often forgo vaccinations for reasons of accessibility, which 
can leave large pockets of nonvaccinated susceptible subjects 
who not only have disease themselves but also facilitate trans-
mission to others who are unable to be immunized, thus breaking 
the protective barrier herd immunity provides. The observed 
spike in incidents of pertussis and measles in children and adults 
in the United States indicates a need for effective public education 
to counter antivaccination proponents whose fear of vaccine side 
effects form pockets of susceptibility and opportunity for spread 
of pathogens among those who are immunocompromised or 
otherwise unable to receive a vaccine. The more accessible we 
make vaccination through education programs, minute clinics, 
job-site resources, and decreased costs, the more effective 
vaccination programs will be. Governments, scientists, and 
citizens will have to commit resources equivalent to the diversity 
and abundance of the pathogens we fight to reach the goal of 
protection from disease and eradication of pathogens through 
vaccination.
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